Stanley Roberts

Experience

• 

  Sandoz Research Institute

  Jan 1981 - Aug 1990

  Section Head/Senior Research Investigator

  Supervised scientific staff in General Toxicology, Toxicology Mechanism Laboratory, Acute and Ocular Toxicology labs. - Drug safety representative to various drug development teams and Study Director for a variety of new candidate drugs in discovery/development. - Led research and determined lack of human risk for rat Leydig cell tumors induced by Sandoz calcium channel blocker drug candidate. Also led research to determine mechanism and potential human relevance of cataracts in animals induced by a Sandoz HMG-CoA reductase inhibitor drug.; Provided over 50 lectures at various undergraduate, graduate and post-graduate organizations discussing various aspects of the pharmaceutical industry and the role of preclinical safety disciplines in drug development. Show less

• 

  Abbott Laboratories

  Aug 1990 - Dec 2005

  Preclinical Drug Metabolism and Pharmacokinetics - Provided vision and managed ADME/PK research and personnel across the Abbott global organization. - Led successful restructuring, reorientation and reorganization of all ADME/PK research to improve clinical success of new drug candidate molecules. - Preclinical development lead for numerous potential in-licensing activities. Supervised scientific staff in General Toxicology, Genetic and In Vitro Toxicology lab, drug safety representative to various drug development teams and Study Director for a variety of new candidate drugs in discovery/development. - Significant contribution to the resolution for lack of human risk from rat Leydig cell tumors induced by Abbott proton pump inhibitor drug candidate

  • Global Director

    Sept 1997 - Dec 2005

  • Section Head/Senior Research Investigator

    Aug 1990 - Sept 1997
• 

  CovX Research, LLC

  Jan 2006 - May 2010

  Vice President ­ Preclinical Development

  Primary or co-author for all aspects of toxicology sections of four successful IND filings on novel CovX monoclonal antibody therapeutics. Primary or co-contributor with responsibility for all aspects of designing, monitoring and reporting of toxicology/pathology studies. - Managed and supervised discovery focused vivarium.

• 

  SAR Safety Assessment

  May 2010 - now

  President

  An independent consulting company specializing in toxicology, drug metabolism (ADME), pharmacokinetics (PK) and drug development. Services provided include; planning, monitoring and reporting all types of preclinical development studies. Additionally, scientific and regulatory strategies for mechanistic problem solving and addressing regulatory issues for new (and existing) projects are also provided.